| pubmed-article:17296442 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17296442 | lifeskim:mentions | umls-concept:C0021368 | lld:lifeskim |
| pubmed-article:17296442 | lifeskim:mentions | umls-concept:C0005682 | lld:lifeskim |
| pubmed-article:17296442 | lifeskim:mentions | umls-concept:C1517004 | lld:lifeskim |
| pubmed-article:17296442 | lifeskim:mentions | umls-concept:C0442124 | lld:lifeskim |
| pubmed-article:17296442 | lifeskim:mentions | umls-concept:C0527067 | lld:lifeskim |
| pubmed-article:17296442 | lifeskim:mentions | umls-concept:C0123882 | lld:lifeskim |
| pubmed-article:17296442 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:17296442 | pubmed:dateCreated | 2007-2-13 | lld:pubmed |
| pubmed-article:17296442 | pubmed:abstractText | Interstitial cystitis is a painful bladder disease characterized by urgency, frequency and variable inflammation but there is no curative therapy. Suplatast tosilate (IPD-1151T) is an immunoregulatory compound that decreases interstitial cystitis symptoms but to our knowledge its mechanism of action is unknown. We investigated the effect of intravesical IPD-1151T on mediator release from bladder explants in experimental cystitis. | lld:pubmed |
| pubmed-article:17296442 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17296442 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17296442 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17296442 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:17296442 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17296442 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17296442 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17296442 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17296442 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17296442 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17296442 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:17296442 | pubmed:issn | 0022-5347 | lld:pubmed |
| pubmed-article:17296442 | pubmed:author | pubmed-author:TheoharidesT... | lld:pubmed |
| pubmed-article:17296442 | pubmed:author | pubmed-author:CatMM | lld:pubmed |
| pubmed-article:17296442 | pubmed:author | pubmed-author:BoucherWW | lld:pubmed |
| pubmed-article:17296442 | pubmed:author | pubmed-author:KempurajDD | lld:pubmed |
| pubmed-article:17296442 | pubmed:author | pubmed-author:PapaliodisDD | lld:pubmed |
| pubmed-article:17296442 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17296442 | pubmed:volume | 177 | lld:pubmed |
| pubmed-article:17296442 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17296442 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17296442 | pubmed:pagination | 1186-90 | lld:pubmed |
| pubmed-article:17296442 | pubmed:dateRevised | 2007-12-3 | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:meshHeading | pubmed-meshheading:17296442... | lld:pubmed |
| pubmed-article:17296442 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17296442 | pubmed:articleTitle | Intravesical suplatast tosilate (IPD-1151T) inhibits experimental bladder inflammation. | lld:pubmed |
| pubmed-article:17296442 | pubmed:affiliation | Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts-New England Medical Center, Boston, Massachusetts 02111, USA. | lld:pubmed |
| pubmed-article:17296442 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17296442 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:17296442 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
